课题基金 / 基金详情

项目摘要

项目成果

Charles Dennis Smith的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Alzh¿imer's disease (AD) is preceded by a period when detectable changes in brain function occur without warning symptoms. This period may be twenty years or longer. Activation measured by functional magnetic resonance imaging is reduced during confi_ntation naming in normal women who have increased risk of late-onset Alzbeimer's disease, at an average age of only 53 years. These same individuals have reduced activation in the posterior cingulat¿ cortex during a memorization task, among other disparities. Our hypothesis is that the altered functional MRI responses in naming, working memory and memorization will quantifiably worsen with age, due to progressive underlying Alzheimcr's disease pathology. Disease-modifying treatments applied in this early, pre-symptomatic stage of AD could have profound impact, by preventing the onset of cognitive symptoms. Millions are currently being spent on large-scale prevention trials, with AD symptoms as end-points. By providing a biomarker ofpre-symptomatic AD progression, fMRI could potentially reduce the duration and costs of such trials. This continuation proposal is designed to detect changes in brain function in high-AD risk individuals over time. We will study normal education-matched groups of high- and low-AD risk subjects in the age ranges 40-65 and 65-90 years, using fMRI stimulus tasks which have previously demonstrated regional disparities in high-AD risk individuals. In addition, we will repeat the naming and fluency fMRI studies performed previously in high- and low-AD risk individuals after an interval of five years, in order to detect longitudinal changes in activation. The convergence of evidence from these cross-sectional and longitudinal studies could provide powerful evidence for a model of Alzheimer's disease as a relentless, slowly progressive brain pathology that begins early in adult life, but remains compensated until it produces clinical symptoms in its late stages.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.neuroimage.2010.05.036
发表时间: 2010-10-01
期刊: NEUROIMAGE
影响因子: 5.7
作者: [Gold, Brian T., Powell, David K., Andersen, Anders H., Smith, Charles D.]
通讯作者: Smith, Charles D.
DOI: 10.1002/jmri.21692
发表时间: 2009-06
期刊: JOURNAL OF MAGNETIC RESONANCE IMAGING
影响因子: 4.4
作者: [Smith, Charles D., Lori, Nicolas F., Akbudak, Erbil, Sorar, Ertugrul, Gultepe, Eren, Shimony, Joshua S., McKinstry, Robert C., Conturo, Thomas E.]
通讯作者: Conturo, Thomas E.
DOI: 10.1002/cem.1172
发表时间: 2008-09
期刊: JOURNAL OF CHEMOMETRICS
影响因子: 2.4
作者: [Rayens, William, Liu, Yushu, Andersen, Anders, Smith, Charles]
通讯作者: Smith, Charles
DOI: 10.1017/s1355617708081381
发表时间: 2008-11
期刊: Journal of the International Neuropsychological Society : JINS
影响因子: --
作者: [Conturo TE, Williams DL, Smith CD, Gultepe E, Akbudak E, Minshew NJ]
通讯作者: Minshew NJ
7
    Essential Siemens Prisma Fit Upgrade for the University of Kentucky 3T Research Scanner
    • 批准号:
      9274596
    • 项目类别:
    • 资助金额:
      $81.34万
    • 财政年份:
      2017
    • 负责人:
      Charles Dennis Smith
    • 依托单位:
    A High-Field Small Animal MR Imager for Biomedical Research
    • 批准号:
      7839523
    • 项目类别:
    • 资助金额:
      $309.59万
    • 财政年份:
      2010
    • 负责人:
      Charles Dennis Smith
    • 依托单位:
    Upgrade to Multiuser 3T Magnetic Resonance Imager
    • 批准号:
      7596804
    • 项目类别:
    • 资助金额:
      $50.0万
    • 财政年份:
      2009
    • 负责人:
      Charles Dennis Smith
    • 依托单位:
    Imaging Brain Function/Structure in Presymptomatic FTD
    • 批准号:
      7457725
    • 项目类别:
    • 资助金额:
      $28.59万
    • 财政年份:
      2006
    • 负责人:
      Charles Dennis Smith
    • 依托单位:
    国内基金
    海外基金
    补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
    靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
    • 批准号:
      JCZRQN202500010
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
    • 依托单位:
    对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
    • 批准号:
      2025JJ70209
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      雷芬芳
    • 依托单位:
    AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      万荣
    • 依托单位: